Loydie Jerome-Majewska

Dr. Loydie Jerome-Majewska


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2012 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
DMDonna M McDonald-McGinn
Donna M McDonald-McGinn
SFSomayyeh Fahiminiya
Somayyeh Fahiminiya
TRTimothée Revil
Timothée Revil
BNBeata A Nowakowska
Beata A Nowakowska
JSJoshua Suhl
Joshua Suhl
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
Background: 22q11.2 deletion syndrome (22q11.2DS) is the most common microdeletion disorder, affecting an estimated 1 : 2000–4000 live births. Patients with 22q11.2DS have a broad spectrum of phenotypic abnormalities which generally includes congenital cardiac abnormalities, palatal anomalies, and immunodeficiency. Additional findings, such as skeletal anomalies and autoimmune disorders, can confer significant morbidity in a subset of patients. 22q11.2DS is a contiguous gene DS and over 40 genes are deleted in patients; thus deletion of several genes within this region contributes to the clinical features. Mutations outside or on the remaining 22q11.2 allele are also known to modify the phenotype. Methods: We utilised whole exome, targeted exome and/or Sanger sequencing to examine the genome of 17 patients with 22q11.2 deletions and phenotypic features found in <10% of affected individuals. Results and conclusions: In four unrelated patients, we identified three novel mutations in SNAP29, the gene implicated in the autosomal recessive condition cerebral dysgenesis, neuropathy, ichthyosis and keratoderma (CEDNIK). SNAP29 maps to 22q11.2 and encodes a soluble SNARE protein that is predicted to mediate vesicle fusion at the endoplasmic reticulum or Golgi membranes. This work confirms that the phenotypic variability observed in a subset of patients with 22q11.2DS is due to mutations on the non-deleted chromosome, which leads to unmasking of autosomal recessive conditions such as CEDNIK, Kousseff, and a potentially autosomal recessive form of Opitz G/BBB syndrome. Furthermore, our work implicates SNAP29 as a major modifier of variable expressivity in 22q11.2 DS patients.

23 June 2010 in BMC Genomics
Verified
Journal Article
Open access
PDF file
TRTimothée Revil
Timothée Revil
DGDaniel Gaffney
Daniel Gaffney
CDChristel Dias
Christel Dias
JMJacek Majewski
Jacek Majewski
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
Alternative splicing is known to increase the complexity of mammalian transcriptomes since nearly all mammalian genes express multiple pre-mRNA isoforms. However, our knowledge of the extent and function of alternative splicing in early embryonic development is based mainly on a few isolated examples. High throughput technologies now allow us to study genome-wide alternative splicing during mouse development. A genome-wide analysis of alternative isoform expression in embryonic day 8.5, 9.5 and 11.5 mouse embryos and placenta was carried out using a splicing-sensitive exon microarray. We show that alternative splicing and isoform expression is frequent across developmental stages and tissues, and is comparable in frequency to the variation in whole-transcript expression. The genes that are alternatively spliced across our samples are disproportionately involved in important developmental processes. Finally, we find that a number of RNA binding proteins, including putative splicing factors, are differentially expressed and spliced across our samples suggesting that such proteins may be involved in regulating tissue and temporal variation in isoform expression. Using an example of a well characterized splicing factor, Fox2, we demonstrate that changes in Fox2 expression levels can be used to predict changes in inclusion levels of alternative exons that are flanked by Fox2 binding sites. We propose that alternative splicing is an important developmental regulatory mechanism. We further propose that gene expression should routinely be monitored at both the whole transcript and the isoform level in developmental studies

27 December 2019 in Genetics Research
Verified
Journal Article
Open access
PDF file
RARachel Aber
Rachel Aber
WCWesley Chan
Wesley Chan
SMSevane Mugisha
Sevane Mugisha
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
Regulated transport through the secretory pathway is essential for embryonic development and homeostasis. Disruptions in this process impact cell fate, differentiation and survival, often resulting in abnormalities in morphogenesis and in disease. Several congenital malformations are caused by mutations in genes coding for proteins that regulate cargo protein transport in the secretory pathway. The severity of mutant phenotypes and the unclear aetiology of transport protein-associated pathologies have motivated research on the regulation and mechanisms through which these proteins contribute to morphogenesis. This review focuses on the role of the p24/transmembrane emp24 domain (TMED) family of cargo receptors in development and disease.

21 April 2020 in Developmental Dynamics
Verified
Journal Article
Open access
PDF file
MBMarie‐Claude Beauchamp
Marie‐Claude Beauchamp
SASabrina Shameen Alam
Sabrina Shameen Alam
SKShruti Kumar
Shruti Kumar
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
Mutations in core components of the spliceosome are responsible for a group of syndromes collectively known as spliceosomopathies. Patients exhibit microcephaly, micrognathia, malar hypoplasia, external ear anomalies, eye anomalies, psychomotor delay, intellectual disability, limb, and heart defects. Craniofacial malformations in these patients are predominantly found in neural crest cells‐derived structures of the face and head. Mutations in eight genes SNRPB, RNU4ATAC, SF3B4, PUF60, EFTUD2, TXNL4, EIF4A3, and CWC27 are associated with craniofacial spliceosomopathies. In this review, we provide a brief description of the normal development of the head and the face and an overview of mutations identified in genes associated with craniofacial spliceosomopathies. We also describe a model to explain how and when these mutations are most likely to impact neural crest cells. We speculate that mutations in a subset of core splicing factors lead to disrupted splicing in neural crest cells because these cells have increased sensitivity to inefficient splicing. Hence, disruption in splicing likely activates a cellular stress response that includes increased skipping of regulatory exons in genes such as MDM2 and MDM4, key regulators of P53. This would result in P53‐associated death of neural crest cells and consequently craniofacial malformations associated with spliceosomopathies.

1 October 2010 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NANatascia Anastasio
Natascia Anastasio
TBTawfeg Ben-Omran
Tawfeg Ben-Omran
ATAhmad Teebi
Ahmad Teebi
KHKevin C.H. Ha
Kevin C.H. Ha
ELEmilie Lalonde
Emilie Lalonde
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska

1 May 2010 in Developmental Biology
Verified
Journal Article
Closed access
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
TATala Achkar
Tala Achkar
LLLi Luo
Li Luo
FLFloria Lupu
Floria Lupu
ELElizabeth Lacy
Elizabeth Lacy